|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
45,530,000 |
Market
Cap: |
51.90(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6 - $1.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Passage Bio is a genetic medicines company focused on developing therapies for monogenic central nervous system disorders. Co. is developing PBGM01, which utilizes a proprietary AAVhu68 capsid for the treatment of GM1 gangliosidosis. Co. is also developing PBFT02, which utilizes an AAV1 capsid for the treatment of frontotemporal dementia-progranulin deficiency. Co. is also developing PBKR03, which utilizes a proprietary AAVhu68 capsid for the treatment of Krabbe disease. Co. has various programs in the research stage under its license agreement with the Trustees of the University of Pennsylvania including: PBML04 for metachromatic leukodystrophy and PBAL05 for amyotrophic lateral sclerosis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,192,577 |
1,192,577 |
Total Buy Value |
$0 |
$0 |
$1,001,765 |
$1,001,765 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
2 |
2 |
Total Shares Sold |
0 |
45,406 |
56,859 |
65,593 |
Total Sell Value |
$0 |
$41,507 |
$51,586 |
$62,246 |
Total People Sold |
0 |
3 |
4 |
6 |
Total Sell Transactions |
0 |
5 |
6 |
9 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Borthwick Kathleen |
SVP, INTERIM CFO |
|
2024-02-13 |
4 |
S |
$0.97 |
$1,426 |
D/D |
(1,470) |
28,466 |
|
-16% |
|
Forman Mark S |
CHIEF MEDICAL OFFICER |
|
2024-02-13 |
4 |
S |
$0.97 |
$1,589 |
D/D |
(1,638) |
48,631 |
|
-16% |
|
Borthwick Kathleen |
SVP, INTERIM CFO |
|
2024-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
29,936 |
|
- |
|
Forman Mark S |
CHIEF MEDICAL OFFICER |
|
2024-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
50,269 |
|
- |
|
Borthwick Kathleen |
SVP, Interim CFO |
|
2024-01-02 |
4 |
S |
$0.91 |
$9,712 |
D/D |
(10,672) |
25,936 |
|
-64% |
|
Forman Mark S |
Chief Medical Officer |
|
2024-01-02 |
4 |
S |
$0.91 |
$14,390 |
D/D |
(15,813) |
45,269 |
|
-64% |
|
Cale Edgar B. |
GC & Corporate Secretary |
|
2024-01-02 |
4 |
S |
$0.91 |
$14,390 |
D/D |
(15,813) |
45,995 |
|
-64% |
|
Borthwick Kathleen |
SVP, Interim CFO |
|
2023-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
36,608 |
|
- |
|
Forman Mark S |
Chief Medical Officer |
|
2023-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
61,082 |
|
- |
|
Cale Edgar B. |
GC & Corporate Secretary |
|
2023-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
61,808 |
|
- |
|
King Simona |
Chief Financial Officer |
|
2023-07-28 |
4 |
S |
$0.88 |
$10,079 |
D/D |
(11,453) |
23,994 |
|
29% |
|
King Simona |
Chief Financial Officer |
|
2023-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,250 |
35,447 |
|
- |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2023-06-28 |
4 |
B |
$0.84 |
$483,164 |
I/I |
575,195 |
8,034,000 |
1.5 |
-20% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2023-06-27 |
4 |
B |
$0.84 |
$518,601 |
I/I |
617,382 |
7,458,805 |
1.5 |
-18% |
|
King Simona |
Chief Financial Officer |
|
2023-04-18 |
4 |
S |
$1.05 |
$2,156 |
D/D |
(2,053) |
2,053 |
|
29% |
|
King Simona |
Chief Financial Officer |
|
2023-04-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
6,250 |
|
- |
|
Kapadia Sandip |
Director |
|
2022-12-01 |
4 |
AS |
$1.19 |
$5,965 |
D/D |
(5,000) |
0 |
|
-10% |
|
Toernsen Monika Maria |
Chief Commercial Officer |
|
2022-09-19 |
4 |
S |
$1.51 |
$2,539 |
D/D |
(1,681) |
3,319 |
|
9% |
|
Toernsen Monika Maria |
Chief Commercial Officer |
|
2022-09-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2022-05-04 |
4 |
B |
$1.94 |
$588,790 |
I/I |
303,500 |
6,841,423 |
1.5 |
-25% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2022-05-03 |
4 |
B |
$1.93 |
$427,495 |
I/I |
221,500 |
6,537,923 |
1.5 |
-13% |
|
Goldsmith Bruce A |
CEO and President |
|
2022-03-21 |
4 |
B |
$3.15 |
$31,500 |
D/D |
10,000 |
15,983 |
2.81 |
-39% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2022-01-20 |
4/A |
B |
$5.00 |
$254,000 |
I/I |
50,800 |
6,316,423 |
1.5 |
- |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2022-01-20 |
4 |
B |
$5.42 |
$2,000,522 |
I/I |
369,100 |
6,634,723 |
1.5 |
-63% |
|
Orbimed Capital Gp Vii Llc |
10% Owner |
|
2022-01-19 |
4 |
B |
$5.11 |
$221,263 |
I/I |
43,300 |
6,265,623 |
1.5 |
-62% |
|
61 Records found
|
|
Page 1 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|